Dr. Lal PathLabs Launches India’s First Comprehensive Complement Lab, Bolstering Autoimmune Diagnostics Portfolio
Dr. Lal PathLabs (NSE: LALPATHLAB) announces the launch of India’s first Comprehensive Complement Testing Laboratory, a strategic move to address the growing incidence of autoimmune disorders and strengthen its specialized diagnostics portfolio. This press release is a regulatory filing under SEBI LODR Regulations.